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Abstract
Purpose: MAP3865c, a Mycobacterium avium subspecies paratuberculosis (MAP) cell membrane protein, has a relevant
sequence homology with zinc transporter 8 (ZnT8), a beta-cell membrane protein involved in Zn++ transportation. Recently,
antibodies recognizing MAP3865c epitopes have been shown to cross-react with ZnT8 in type 1 diabetes patients. The
purpose of this study was to detect antibodies against MAP3865c peptides in patients with high-risk proliferative diabetic
retinopathy and speculate on whether they may somehow be involved in the pathogenesis of this severe retinal disorder.
Methods: Blood samples were obtained from 62 type 1 and 80 type 2 diabetes patients with high-risk proliferative diabetic
retinopathy and 81 healthy controls. Antibodies against 6 highly immunogenic MAP3865c peptides were detected by
indirect ELISA.
Results: Type 1 diabetes patients had significantly higher rates of positive antibodies than controls. Conversely, no
statistically significant differences were found between type 2 diabetes patients and controls. After categorization of type 1
diabetes patients into two groups, one with positive, the other with negative antibodies, we found that they had similar
mean visual acuity (,0.6) and identical rates of vitreous hemorrhage (28.6%). Conversely, Hashimoto’s thyroiditis prevalence
was 4/13 (30.7%) in the positive antibody group and 1/49 (2%) in the negative antibody group, a statistically significant
difference (P= 0.016).
Conclusions: This study confirmed that type 1 diabetes patients have significantly higher rates of positive antibodies
against MAP/ZnT8 peptides, but failed to find a correlation between the presence of these antibodies and the severity
degree of high-risk proliferative diabetic retinopathy. The significantly higher prevalence of Hashimoto’s disease among
type 1 diabetes patients with positive antibodies might suggest a possible common environmental trigger for these
conditions.
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Diabetes mellitus is the most common endocrine disorder in
industrialized countries. Two main forms are recognized [1]. Type
1 diabetes (T1D) is due to a deficiency in endogenous insulin
secretion secondary to destruction of insulin-producing beta cells
in the pancreas. Although T1D does have a peak incidence around
the time of puberty, approximately 25% of cases present after 35
years of age. Type 2 diabetes (T2D) is characterized by insulin
resistance with an insulin secretory defect leading to relative
insulin deficiency. This group accounts for 90–95% of patients
with diabetes and also has a strong genetic predisposition. T2D
patients are usually, but not always, older than age 40 at
presentation. Obesity is a frequent finding and, in the United
States, is present in 80–90% of these patients.
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Diabetic retinopathy is the leading cause of new cases of legal
blindness among working-age people in developed countries.
Proliferative diabetic retinopathy (PDR), the most vision-threat-
ening form of diabetic retinopathy, has been reported to be
present in approximately 50% of T1D patients with 25 years’
duration of the disease and in 25% of patients who have had T2D
for 25 years or more [2,3].
Zinc transporter 8 (ZnT8), a pancreas beta-cell membrane
protein involved in Zn++ transportation, may act as a major
autoantigen in T1D [4]. Auto-antibodies against ZnT8 have been
found in 60–80% of newly-diagnosed cases of T1D [5].
Furthermore, dysregulation in Zn++ homeostasis caused by
ZnT8 downregulation has been implicated in the pathogenesis
of ischemic retinopathy [6]. Mycobacterium avium subspecies
paratuberculosis (MAP) is transmitted from dairy herds to humans
through food contamination. MAP causes an asymptomatic
infection that is highly prevalent in patients with T1D, compared
to those with T2D and healthy controls [7,8]. MAP3865c, a MAP
cell membrane protein, has been shown to display a relevant
sequence homology with ZnT8 [4,9]. Moreover, antibodies
recognizing MAP3865c epitopes have been found to cross-react
with ZnT8 in T1D patients [4,9,10].
We are unaware of any former study investigating a possible
role of auto-antibodies against MAP/ZnT8 epitopes in the
pathogenesis of PDR. The purpose of this study was to detect
antibodies against 6 highly immunogenic MAP3865c peptides in
patients with high-risk PDR, the most severe form of PDR, and in
healthy controls and speculate on whether, or not, these antibodies
may somehow be involved in the pathogenesis of PDR.
Methods
Patients and Controls
The present study used a case-control design, recruiting 62 T1D
and 80 T2D patients with high-risk PDR and 81 healthy controls,
all accrued between January and December 2013.
The inclusion criteria for the case group were diagnosis of T1D
or T2D with high-risk PDR and age $18 years. Both newly-
diagnosed cases of high-risk PDR and well-established cases,
already treated with retinal laser photocoagulation, were included.
According to the Early Treatment of Diabetic Retinopathy Study
(ETDRS) classification, the diagnosis of high-risk PDR was made
by the detection of new vessels on or within one disc diameter of
the optic disc equaling or exceeding standard photograph 10A
(about 1/4 to 1/3 disc area), with or without vitreous or preretinal
hemorrhage; or vitreous and/or preretinal hemorrhage accompa-
nied by new vessels either on the optic disc less than standard
photograph 10A or new vessels elsewhere equaling or exceeding
1/4 disc area on ophthalmoscopic examination and fluorescein
angiography [11,12]. Plasma glucose, creatinine, and glycated
hemoglobin (HbA1c), and medical conditions, including body mass
index (BMI), systemic hypertension, hypercholesterolemia, diabet-
ic nephropathy, peripheral neuropathy, and cardio- and cerebro-
vascular status were recorded. All diabetic patients underwent a
full ophthalmic evaluation, including best corrected visual acuity
(BCVA), slit-lamp examination, applanation tonometry, fundus
biomicroscopy, and fluorescein angiography. Exclusion criteria
included any level of non-Sardinian ancestry and evidence of any
other retinal vascular disorder.
Apparently healthy subjects, recruited from accompanying
relatives or friends of patients or from hospital personnel, were
used as controls. Exclusion criteria included clinical/laboratory
evidence of diabetes mellitus, age ,18 years, any level of non-
Sardinian ancestry, and previous history of retinal artery
occlusion, retinal vein occlusion, or anterior ischemic optic
neuropathy. All controls underwent standard ophthalmic evalua-
tion, including BCVA, slit-lamp examination, applanation tonom-
etry, and fundus examination. Plasma glucose, systolic and
diastolic blood pressure, and medical conditions were also
recorded.
Subjects were classified as diabetic if they were under treatment
for T1D or T2D or if they had a fasting plasma glucose level of $
126 mg/dL and/or a plasma glucose level of $200 mg/dL
2 hours after a 75-g oral glucose load in a glucose tolerance test (as
defined by the WHO). Subjects were considered to have
hypertension if they were receiving treatment with anti-hyperten-
sion drugs or if their blood pressure was .140 mm Hg systolic or
.90 mm Hg diastolic (as defined by the WHO/International
Society of Hypertension). Hypercholesterolemia was defined by a
fasting plasma cholesterol level of $200 mg/dL or the intake of
lipid-lowering drugs.
Approval from the Ethics Committee/Institutional Review
Board of the Department of Surgical, Microsurgical, and Medical
Sciences, University of Sassari, Sassari, Italy, was obtained and the
study was conducted in full accord with the tenets of the
Declaration of Helsinki. Each participant received detailed
information and provided written informed consent before
inclusion.
Eight percent of the cases and 10% of the controls who were
eligible for the study declined to participate. The major reason was
‘‘not interested’’.
Categorical values were compared by Chi-square test. The
differences between cases and controls for quantitative variables
were analyzed by Student’s t test or Mann-Whitney test, when
appropriate.
Blood collection
A blood sample was taken from each participant. Five ml of
peripheral blood was collected in Vacutainer Serum tubes,
transported at room temperature, left to clot for 15–30 minutes,
and finally centrifuged at 20006g for 10 minutes for plasma and
serum separation. The supernatant serum was removed, stored at
280uC, and analyzed within 6 months.
Peptides
Six MAP/ZnT8 peptides were synthesized at .90% purity
(LifeTein, South Plainfield, NJ 07080, USA). Four fell within the
transmembrane region [MAP3865c125–133 (MIAVALAGL), MAP
3865c133–141 (LAANFVVAL), MAP3865c246–252 (LSPGKDM),
MAP3865c256–262 (HLISTGD)] and two were homologues to the
human C-terminal ZnT8 immunogenic region [MAP3865c261–267
(GDSARVL) and MAP3865c281–287 (HATVQID)].
Enzyme-Linked Immunosorbent Assay (ELISA)
Antibodies specific for MAP3865c peptides were detected by
indirect ELISA, as described previously [9]. Receiver operating
characteristic (ROC) curves were used to calculate the cut-off
values for positivity. The specificity was set at 93.8% (i.e. Ab +
healthy controls ,6.2%). The Area Under ROC Curve (AUC)
and the percent fraction of antibody + sera were determined.
Results were assessed by Fisher exact test and P values#0.05 were
considered to be statistically significant. Statistical analysis was
performed with commercial software (Graphpad Prism 6.0).
ELISA results were normalized to a strongly positive control
serum tested in all experiments, whose reactivity was set at 10.000
arbitrary units (AU)/ml. ELISA precision was determined by
calculating both the inter- and intra-assay coefficients of variation
(CV).
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Results
The study group consisted of 62 T1D patients (mean age:
48.6613.5 years; mean diabetes duration: 32.169.9 years) and 80
T2D patients (mean age: 66.667.4 years; mean diabetes duration:
15.168.5 years), all with bilateral high-risk PDR. The systemic
characteristics of T1D and T2D patients are reported in Table 1.
Both had similar median values of plasma glucose, creatinine, and
glycated hemoglobin and similar rates of systemic hypertension,
hypercholesterolemia, diabetic nephropathy, peripheral neuropa-
thy, and Hashimoto’s thyroiditis. Conversely, mean BMI was
significantly higher in T2D patients, thus confirming that obesity is
a frequent finding in T2D. Median glycated hemoglobin was 7.7
(61 mmol/mol) in T1D patients and 7.2 (55 mmol/l) in T2D
patients, a result indicating poor glycemic control.
The control group consisted of 81 healthy subjects (39 men, 42
women; mean age: 48612 years).
ELISA intra-assay CV ranged from 5.3% to 6.8%, whereas
inter-assay CV ranged from 7.5% to 8.1%. These low CV values
confirm that the results were consistent throughout the study.
Results on the detection of antibodies against MAP/ZnT8
peptides in T1D and T2D patients compared to healthy controls
are summarized in Figures 1, 2, 3. All six peptides were highly
recognized and showed detectable reactivity. T1D patients had
significantly higher rates of positive antibodies than the control
subjects for 5 out of the 6 MAP/ZnT8 peptides tested. On the
other hand, no statistically significant differences were found
between T2D patients and healthy controls.
In Figures 4 and 5, results on antibodies against MAP/ZnT8
peptides in T1D and T2D patients are compared. T1D patients
showed significantly higher rates of positive antibodies against
MAP3865c125–133, MAP3865c133–141, and MAP3865c246–252.
After categorization of T1D patients into two groups, one with
positive, the other with negative antibodies against MAP/ZnT8
peptides, we found that both had similar systemic characteristics,
with the exception of Hashimoto’s thyroiditis, whose prevalence
was 4/13 (30.7%) in the positive antibody group and 1/49 (2%) in
the negative antibody group, a statistically significant difference
(P=0.016). No antibodies against MAP/ZnT8 peptides were
found in the only T2D patient with Hashimoto’s disease.
Mean visual acuity was 0.6560.36 (range: 0–1) in T1D patients
and 0.5760.36 (range: 0–1) in T2D patients, a not statistically
significant difference. Furthermore, T1D and T2D patients
also had almost identical mean intraocular pressure values
(14.962.4 mm Hg and 15.364.1 mm Hg, respectively). Twelve
(19.4%) T1D patients and 20 T2D patients (25%) had a posterior
chamber intraocular lens. Vitreous hemorrhage was observed in
18 (29%) T1D and in 20 (25%) T2D patients. After categorization
of T1D patients into two groups, one with positive, the other with
negative antibodies against MAP/ZnT8 peptides, we found that
they had similar mean BCVA (0.6760.36 and 0.6160.35,
respectively) and identical rates of vitreous hemorrhage (28.6%).
Discussion
T1D is one of the most common autoimmune disorders,
characterized by a T cell-mediated destruction of insulin-
producing beta cells in the pancreas. This condition is believed
to result from the interaction between multiple genetic and
environmental factors, many of which are still poorly understood
[13]. Former studies have shown that auto-antibodies against
ZnT8 are common in newly-diagnosed cases of T1D [5], thus
suggesting that this beta-cell membrane protein may act as a major
autoantigen in T1D [4]. More recent investigations have found
that antibodies against MAP3865c epitopes cross-react with ZnT8
epitopes [4,9,10], a result which could imply molecular mimicry
between mycobacterial and pancreas beta-cell epitopes and raises
the interesting question of whether MAP infection may be a
potential environmental trigger for T1D. This finding, originally
seen in T1D patients from Sardinia [4,9,10], an Italian island in
Table 1. Systemic characteristics of T1D and T2D patients with high-risk proliferative diabetic retinopathy (PDR).
T1D patients T2D patients P
(n = 62) (n =80) T1D vs. T2D
Age, years, mean ± S.D. 8.6613.5 66.667.4 ,0.0001a
Gender
- men, n. (%) 31 (50) 51 (63.8) 0.5b
- women, n. (%) 31 (50) 29 (36.2) 0.4b
Body mass index, mean ± S.D. 25.464 28.564.8 0.0001a
Diabetes duration, years, mean ± S.D. 32.169.9 15.168.5 ,0.0001a
Plasma glucose, mg/dL, median (95% C.I.) 155 (150–171) 149 (140–160) 0.288c
Plasma creatinine, mg/dL, median (95% C.I.) 0.85 (0.79–0.91) 0.85 (0.76–0.9) 0.822c
HbA1c, %, median (95% C.I.) 7.7 (7.4–8) 7.2 (6.8–8.2) 0.074
c
HbA1c, mmol/mol, median (95% C.I.) 61 (57–64) 55 (51–66) 0.074
c
Systemic hypertension, n. (%) 32 (51.6) 58 (72.5) 0.25b
Hypercholesterolemia, n. (%) 26 (41.9) 40 (50) 0.63b
Diabetic nephropathy, n. (%) 1 (1.6) 5 (6.3) 0.36b
Peripheral neuropathy, n. (%) 3 (4.8) 0 (0) 0.18b
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the middle of the Mediterranean Sea, was later also observed in
T1D patients from mainland Italy [8,10].
There is a lot of experimental evidence indicating that Zn++ is
abundant in the retina, where it plays an essential role in cell
survival and in the normal functioning of antioxidant enzymes
[6,14–16]. Recently, dysregulation in Zn++ homeostasis caused by
ZnT8 downregulation has been implicated in the pathogenesis of
ischemic retinopathy [6]. Therefore, it is theoretically possible that
ZnT8 downregulation might also be involved in the pathogenesis
of PDR, because retinal ischemia caused by capillary occlusion is
an essential step in the development of this vision-threatening
vascular disorder. The detection of antibodies against MAP3865c
epitopes cross-reacting with ZnT8 epitopes, associated with a
more severe form of PDR with lower visual acuity and higher
prevalence of vitreous hemorrhage, might provide an indirect sign
of a possible correlation between ZnT8 dysregulation and DR. In
this survey, in order to investigate this hypothesis, serum
antibodies against 6 MAP/ZnT8 peptides were detected in high-
risk PDR patients and healthy controls. We found that T1D
patients had significantly higher rates of positive antibodies than
the control subjects, a result consistent with former studies
[4,9,10]. Similarly, T1D patients showed significantly higher rates
of positive antibodies than T2D patients. On the other hand, no
statistically significant differences were found between T2D
patients and controls. Overall, these results confirm the association
between T1D and the detection of antibodies against MAP/ZnT8
peptides, thus corroborating the hypothesis that MAP infection
may be a potential environmental trigger for T1D.
In this study, T1D and T2D patients with high-risk PDR
showed similar mean values of BCVA and had similar rates of
vitreous hemorrhage. Likewise, after categorization of T1D
patients into two groups, one with positive, the other with negative
antibodies against MAP/ZnT8 peptides, we found that they had
similar mean BCVA and identical rates of vitreous hemorrhage.
On the whole, the absence of a more severe form of high-risk PDR
in patients with positive antibodies against MAP/ZnT8 peptides
might imply that auto-immune ZnT8 dysregulation plays a minor
or no role in the pathogenesis of high-risk PDR.
One could argue that our choice of using BCVA and vitreous
hemorrhage as ways of categorizing the severity degree of high-risk
PDR might be questionable. Indeed, BCVA may be affected by
concomitant macular edema and/or ischemia and cataract, all of
Figure 1. Prevalence of anti-MAP3865c antibodies in T1D and T2D patients with high-risk PDR and in healthy controls. Sera were
tested for their reactivity against plate-coated MAP3865c133–141 (A and B) and MAP3865c125–133 (C and D) peptides. Antibody distribution is shown for
T1D (A and C) and T2D (B and D) patients compared to controls. In each essay, the dotted line indicates the cut-off for positivity, as calculated by ROC
analysis. The percent fraction of antibodies + sera is indicated on the top of each distribution, while bars indicate the corresponding median-
interquartile range. AUC and p values determined by Fisher exact test are shown in the top right corner.
doi:10.1371/journal.pone.0107802.g001
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which are common in patients with diabetic retinopathy.
However, there is little doubt that the more serious forms of
high-risk PDR are associated with reduced BCVA and vitreous
hemorrhage. Therefore, we feel strongly that these parameters can
provide a measure of the severity of high-risk PDR.
An unexpected result of post-hoc analysis was the significantly
higher prevalence of Hashimoto’s thyroiditis in the group of T1D
patients with positive antibodies against MAP/ZnT8 peptides. To
the best of our knowledge, we are unaware of any published study
reporting a similar association. This finding is intriguing and raises
the interesting questions of whether T1D and Hashimoto’s disease
share a common pathogenic mechanism and whether T1D
patients with positive antibodies against MAP/ZnT8 peptides
might have a higher risk of developing auto-immune thyroiditis.
In a recent population-based study exploring the prevalence and
comorbidity of 12 auto-immune diseases in Sardinia, Sardu et al.
disclosed that Hashimoto’s thyroiditis is the most common
autoimmune disease and that individuals affected by one
autoimmune disorder are more likely to develop a second one
[17]. Furthermore, experimental and clinical evidence indicates
that MAP may be a potential environmental trigger of
Hashomoto’s thyroiditis, as suggested by the detection of viable
MAP organism and serum antibodies against MAP/ZnT8
peptides in patients suffering from this auto-immune thyroid
disease [18–20].
In ruminants, MAP specifically colonizes the mucosa-associated
lymphoid tissue (MALT) of the small intestine, where this
organism grows and multiplies within the intraepithelial macro-
phages, thus causing Johne’s disease ( JD) [21]. In humans, MAP is
transmitted by the ingestion of contaminated dairy products and
causes an asymptomatic infection, which has been associated not
only with T1D and Hashimotos’s thyroiditis, but also with Crohn’s
disease [22] and multiple sclerosis [23]. Overall, all these data
support the idea that a common pathogenic mechanism may be
responsible for these different autoimmune diseases.
Recent research has shown increased serum concentrations of
CXCL10 chemokine in T1D children with antibodies against
MAP3738c protein [24]. Furthermore, high circulating CXCL10
levels associated with T-helper (Th) 1 autoimmune response have
been observed in new onset T1D and Hasmimoto’s disease
[25,26]. Therefore, the significantly higher prevalence of Hashi-
moto’s thyroiditis among T1D patients with positive antibodies
against MAP/ZnT8 might in part be due to a common immuno-
pathogenic mechanism involving Th 1 immune response and
chemokines.
Figure 2. Prevalence of anti-MAP3865c antibodies in T1D and T2D patients with high-risk PDR and in healthy controls. Sera were
tested for their reactivity against plate-coated MAP3865c246–252 (A and B) and MAP3865c256–262 (C and D) peptides. Antibody distribution is shown for
T1D (A and C) and T2D (B and D) patients compared to controls. Data representation is the same as in Fig. 1.
doi:10.1371/journal.pone.0107802.g002
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Figure 3. Prevalence of anti-MAP3865c antibodies in T1D and T2D patients with high-risk PDR and in healthy controls. Sera were
tested for their reactivity against plate-coated MAP3865c261–267 (A and B) and MAP3865c281–287 (C and D) peptides. Antibody distribution is shown for
T1D (A and C) and T2D (B and D) patients compared to controls. Data representation is the same as in Fig. 1.
doi:10.1371/journal.pone.0107802.g003
Figure 4. Prevalence of anti-MAP3865c antibodies in T1D and T2D patients with high-risk PDR. Sera were tested for their reactivity
against plate-coated MAP3865c133–141 (A) and MAP3865c125–133 (B) peptides. Antibody distribution is compared between T1D and T2D patients. Data
representation is the same as in Fig. 1.
doi:10.1371/journal.pone.0107802.g004
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Our study has several important limitations. First, it was
restricted to a limited, genetically homogeneous group of patients
(i.e. those of Sardinian ancestry); as a result, our findings may not
be applicable to diabetic patients of non-Sardinian ancestry.
Second, we analyzed a relatively small number of subjects. Third,
we do not know whether T1D patients with positive antibodies
against MAP/ZnT8 peptides developed high-risk PDR earlier
than those with negative antibodies. Fourth, in patients suffering
from Hashimoto’s disease, we originally did not collect sufficiently
detailed information about the thyroid condition, as the primary
goal was to investigate the role of antibodies against MAP/ZnT8
peptides in the pathogenesis of high-risk PDR. Last, but not least,
we compared T1D and T2D patients with high-risk PDR to
normal subjects, rather than to diabetic controls without diabetic
retinopathy. This second, potentially more informative compari-
son will be the subject of further investigation.
In conclusion, this study confirmed that T1D patients have
significantly higher rates of positive antibodies against MAP/ZnT8
peptides, but failed to find a correlation between their presence in
the patients’ serum and the degree of severity of high-risk PDR.
On the other hand, we found a significantly higher prevalence of
Hashimoto’s thyroiditis in the group of T1D patients with positive
antibodies. At this stage, no definitive conclusion can be drawn
from our preliminary results. Further and larger clinical and
experimental trials are required to clarify the exact role of
antibodies against MAP/ZnT8 peptides in the pathogenesis of
PDR in T1D and to establish whether, or not, T1D patients are
more susceptible to Hashimoto’s disease.
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